诱导多能干细胞在人类疾病的诊断、药物筛选和治疗中的未来展望。
Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases.
机构信息
Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, HKSAR, China.
出版信息
Thromb Haemost. 2010 Jul;104(1):39-44. doi: 10.1160/TH10-05-0269. Epub 2010 Jun 10.
Recent advances in stem cell biology have transformed the understanding of cell physiology and developmental biology such that it can now play a more prominent role in the clinical application of stem cell and regenerative medicine. Success in the generation of human induced pluripotent stem cells (iPS) as well as related emerging technology on the iPS platform provide great promise in the development of regenerative medicine. Human iPS cells show almost identical properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of their limitations of use. In addition, investigations into reprogramming of somatic cells to pluripotent stem cells facilitate a deeper understanding of human stem cell biology. The iPS cell technology has offered a unique platform for studying the pathogenesis of human disease, pharmacological and toxicological testing, and cell-based therapy. Nevertheless, significant challenges remain to be overcome before the promise of human iPS cell technology can be realised.
近年来,干细胞生物学的进展已经改变了人们对细胞生理学和发育生物学的理解,使得它在干细胞和再生医学的临床应用中能够发挥更突出的作用。人类诱导多能干细胞(iPS)的成功生成以及 iPS 平台上相关新兴技术的发展,为再生医学的发展带来了巨大的希望。iPS 细胞在多能性方面几乎与人类胚胎干细胞(ESC)具有相同的特性,但避免了它们在使用方面的许多限制。此外,对体细胞重编程为多能干细胞的研究促进了对人类干细胞生物学的更深入了解。iPS 细胞技术为研究人类疾病的发病机制、药物和毒理学测试以及基于细胞的治疗提供了一个独特的平台。然而,在实现人类 iPS 细胞技术的承诺之前,仍然需要克服重大挑战。